Core Insights - The investigational medicine zorevunersen shows potential for disease modification in Dravet syndrome, a severe genetic neurodevelopmental disorder, with significant reductions in seizures and improvements in cognition and behavior [1][4][10] Company Overview - Stoke Therapeutics, a biotechnology company focused on RNA medicine, is developing zorevunersen to restore protein expression and treat Dravet syndrome [1][14] - Biogen Inc. collaborates with Stoke Therapeutics to develop and commercialize zorevunersen, retaining exclusive rights in certain regions [10][15] Clinical Study Results - Data from Phase 1/2a studies indicate that zorevunersen led to substantial and durable reductions in seizure frequency, particularly with initial doses of 70 mg [4][11] - Improvements in neurodevelopment, functioning, and quality of life were observed over three years of treatment in open-label extension studies [5][12] Safety Profile - Zorevunersen has been generally well tolerated, with 81 patients evaluated for safety and over 800 doses administered [6][11] - The most common adverse event was elevated cerebrospinal fluid protein levels, with no related clinical manifestations reported [6][12] Future Developments - The ongoing Phase 3 EMPEROR study aims to further evaluate the efficacy and safety of zorevunersen, with results expected in mid-2027 [8][13] - The study will enroll approximately 150 patients and assess the percentage change in major motor seizure frequency as the primary endpoint [13]